Size | Price | |
---|---|---|
1mg | ||
5mg | ||
Other Sizes |
Targets |
Human EPCAM[1]
|
---|---|
ln Vitro |
In B16/EpCAM 3E3 cells, Adecatumumab (4 μM; 18 h) exhibits different kinetic binding activities between human and murine Adecatumumab[2]. Adecatumumab exhibits a dose-dependent antibody response based on the activity of cell-mediated cytotoxicity (ADCC) in natural killer (NK) cells (0.1 ng/mL–0.1 mg/mL; 4 h)[2].
|
ln Vivo |
Both human adecatumumab and mu-adecatumumab (300 μg/mouse; intravenous bolus injection; three times per week) suppress tumor growth in the B16/EpCAM xenograft tumor model in mice[2]. A bi-exponential curve progression of serum concentration is seen for both human adecatumumab and mu-adecatumumab (300 μg/mouse; iv bolus injection; single dosage), with an early distribution phase between 0 and 10 h and a terminal elimination phase[2].
|
Animal Protocol |
Animal/Disease Models: Female immunocompetent C57BL/6 mice ( 6-10 weeks old) with B16/EpCAM (iv)[2]
Doses: 250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab Route of Administration: 250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab Experimental Results: Both of them demonstrated anti-tumor activity against B16/EpCAM cells in mice. Although human adecatumumab inhibited the size of tumor colonies mice, the number of colonies was only slightly decreased after treatment without significant difference. In contrast, mu-adecatumumab induced a highly significant reduction in the number of lung tumor colonies by >85%, and the few remaining tumor colonies were of very small size. |
References |
[1]. Kurtz JE, et al. Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8.
[2]. Lutterbuese P, et al. Exchanging human Fcgamma1 with murine Fcgamma2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung metastasis model. Cancer Immunol Immunother. 2007 Apr;56(4):459-68. |
Molecular Weight |
147.5 (kDa)
|
---|---|
CAS # |
503605-66-1
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.